Amber Patterson, MD, is a physician-scientist and biotechnology innovator advancing the field of allergy and immunology. Her career reflects a consistent focus on innovation, clinical impact, and the translation of scientific advances into scalable solutions for patients with allergic disease.

Dr. Patterson is internationally recognized for her expertise in the ILIT™ Protocol and development of Auni ILIT-certified protocols. While on faculty at The Ohio State University Wexner Medical Center and Nationwide Children’s Hospital, she directed the world’s first pediatric ILIT clinical trial and founded the Center for Immunotherapy, establishing a foundation for U.S.-based ILIT research. She holds multiple patents in allergy therapeutics and diagnostic technologies, underscoring her role in bridging academic discovery with commercial application.

Her leadership in the specialty includes serving on the Joint Task Force for Practice Parameters responsible for revising U.S. guidelines for allergen immunotherapy, chairing the American Academy of Allergy, Asthma & Immunology (AAAAI) Immunotherapy & Diagnostics Committee, and maintaining an academic appointment as Clinical Assistant Professor at the University of Toledo College of Medicine. She is also founder of the Auni ILIT Learning Network, a clinician-driven initiative accelerating the translation of the ILIT Protocol into routine practice.

Dr. Patterson is co-founder and Chief Medical Officer of Auni Therapeutics, LLC, where she leads clinical strategy and translational research to bring next-generation allergen immunotherapies to market